Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

Here's 3 Dividend Companies That Just Crossed Above Their 50 Moving Average

Trading Smarter, Not Harder With the 50-Day Moving Average Strategy

Barchart

Johnson & Johnson proposes paying $8.9 billion to settle talcum powder lawsuits

Under a proposal, a J&J subsidiary will re-file for bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

WEKU

Johnson & Johnson proposes $8.9 billion payout to settle talcum powder lawsuits

A subsidiary of the company will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

As states start to get opioid settlement cash, few are sharing how they spend it

All told, drugmakers and distributors will pay over $50 billion to communities harmed by opioids. An investigation finds that only a dozen states are letting the public see how they use the money.

WEKU

Victory over big pharma opens door to cheaper tuberculosis drugs

India’s patent office turns down bedaquiline extension to Johnson & Johnson, clearing the way for generic versions

The Guardian - UK

The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

StockNews.com

Want to Retire a Millionaire? 2 Stocks to Buy Now

The recent bank failures have increased the likelihood of a recession, with many economists increasing the odds of an economic slump in the next 12 months. Amid this backdrop, investors could buy fundamentally strong stocks, Johnson & Johnson (JNJ) and Pfizer (PFE), which could help retire a millionaire. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

This Big Pharma Stock Is a Clear Buy in 2023

With interest rates expected to be higher than originally anticipated and fears of a looming recession weighing heavily on investors’ decisions, the stock market is expected to remain under pressure this year. Amid this backdrop, it could be wise for investors to invest in Johnson & Johnson (JNJ) due to…

StockNews.com

3 Powerhouse Stocks to Buy in 2023

As the Fed is expected to raise interest rates higher than expected, the revived recession fears will keep the stock market under pressure in the upcoming months. Thus, it could be wise to scoop up shares of high-quality businesses, such as Johnson & Johnson (JNJ), Humana Inc. (HUM), and AutoZone,…

StockNews.com

1 Stock to Buy for Safety in This Volatile Market

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

StockNews.com

Hundreds more tech, life science layoffs jolt East Bay, San Francisco

BERKELEY, Calif. — Hundreds more layoffs affecting tech and life science jobs in the Bay Area have been disclosed by companies in what has morphed into a steady drumbeat of local staffing reductions in the wobbly sectors.

Tribune News Service

Appeals court clears the way for more lawsuits over Johnson's Baby Powder

A U.S. appeals court has dismissed the bankruptcy case filed by a Johnson & Johnson spinoff company. Around 40,000 cancer patients have filed suit, alleging the powder was contaminated with asbestos.

WEKU

Why inventing a vaccine for AIDS is tougher than for COVID

The 4-decades long effort to create an AIDS vaccine suffered a blow with news that a vaccine in a late stage trial was discontinued because results showed it to be ineffective. What are the obstacles?

WEKU

What on Earth Is Aaron Rodgers Talking About?

The Packers quarterback gets asked about trade rumors, calls out woke culture, Big Pharma.

Sports Illustrated

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

J&J subsidiary to pay $9.75M to resolve kickback allegations

Federal prosecutors say a subsidiary of health care company Johnson & Johnson has agreed to pay nearly $10 million to settle allegations that it violated federal and state law by providing free products to a surgeon

Fortune

A guide to purchasing stock in a Fortune 500 company

The steps to purchase a Fortune 500 stock and why they can be a valuable part of your portfolio.

StockNews.com

The 4 Most Attractive Long-Term Stock Picks

With the Fed expected to keep rates higher throughout this year, the odds of the economy tipping into a recession are rising. Amid ongoing macroeconomic uncertainties, investors may consider buying companies with reliable performance over the years for solid long-term returns. To that end, Pfizer (PFE), Johnson & Johnson (JNJ),…

Fortune

The 'Kraken' COVID variant taking hold in the U.S. Here's how many vaccine shots there are—and what experts recommend to protect yourself

The highly transmissible 'Kraken' COVID variant is here. Experts say getting boosted is your best protection.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Vaccines are not making COVID strains like 'Kraken' stronger

Scientists say there is no evidence to suggest that vaccinations are making COVID "stronger" and that mutations are a normal part of virus evolution.

StockNews.com

1 Dividend Stock to Buy Now and Retire on Later

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Tribune News Service

Getting vaccinated this holiday season? Here’s how to stay up-to-date on your COVID shots

DALLAS — Staying on schedule with the COVID-19 vaccine can feel like chasing a moving target.

Al Jazeera

Ebola vaccines produced lasting antibodies during trial: Studies

Studies in West Africa said the vaccines developed by Johnson & Johnson and Merck & Co appear to be safe in children.

Reuters

J&J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies

Ebola vaccines developed by Johnson Johnson and Merck Co produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday.

ABC News

Pelvic mesh victims left unsure of futures as legal fees threaten to slash class action payout

The legal firm representing the thousands of plaintiffs in a class action over dangerous pelvic mesh could take up to a third of the compensation payment.

1 … 11 12 13 14

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.